GLAND vs NEULANDLAB: Stock Comparison
GLAND PHARMA is the larger company by market capitalisation. GLAND PHARMA shows a lower P/E, a higher dividend yield and lower leverage, while NEULAND LAB shows a higher ROE, faster revenue growth and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
GLAND leads 6; NEULANDLAB leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | GLAND | NEULANDLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | GLAND | NEULANDLAB |
|---|---|---|
| Live Price | ₹2,922.3 | ₹23,535 |
| Day Change | -0.83% | -1.11% |
| Volume | 3.89 L | 43,901 |
| 52-Week High | ₹3,042 | ₹24,225 |
| 52-Week Low | ₹1,573.6 | ₹11,500 |
| Distance from 52W High | -3.93% | -2.85% |
Valuation
| Metric | GLAND | NEULANDLAB |
|---|---|---|
| Market Cap | ₹48,333 Cr | ₹30,060 Cr |
| P/E Ratio | 42.78x | 60.39x |
| P/B Ratio | 4.66x | 16.04x |
| EPS | ₹22.09 | ₹115.1 |
| Book Value | ₹627.91 | ₹1,461.02 |
| Dividend Yield | 0.68% | 0.15% |
Growth
| Metric | GLAND | NEULANDLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | 22.3% | 136.4% |
| EPS Growth (TTM YoY) | 96.4% | 664.4% |
| Qtr Sales Growth | -28.53% | 0% |
| Qtr Profit Growth | 14.96% | 0.21% |
Profitability & Leverage
| Metric | GLAND | NEULANDLAB |
|---|---|---|
| ROE | 12.02% | 19.46% |
| ROCE | 17.2% | 19.17% |
| Net Margin | 16.18% | 17.99% |
| Operating Margin | 38.8% | 25.29% |
| Debt to Equity | 0x | 0.11x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | GLAND | NEULANDLAB |
|---|---|---|
| Promoter Holding | 51.77% | 32.62%▼ 0.01 pp |
| FII Holding | 8.74%▲ 1.44 pp | 21.08%▲ 0.62 pp |
| DII Holding | 30.44%▼ 2.91 pp | 16.51%▲ 0.67 pp |
| Public Holding | 9.05%▲ 1.53 pp | 29.79%▼ 1.28 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: GLAND PHARMA and NEULAND LAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.